SKAN Group AG (SKAN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of SKAN Group AG stock CHF 23.41, price CHF 69.70, that is 66.4% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range CHF 40.21 – CHF 89.80 · fair‑value band CHF 15.66 – CHF 29.28 · the CHF 69.70 price screens above the CHF 23.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow SKAN Group in your weekly email
Every Wednesday you see whether SKAN Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables.
Show moreShow less
The company offers accessories, biological indicators, digital ventures, isolators, cleanroom, laminar flow, particle counter, personal protective equipment, safety workbench, transfer systems, and fume cupboard.
It also provides digital solutions, lifecycle support, laboratory services, and SKAN labs. The company was formerly known as BV Holding AG and changed its name to SKAN Group AG in October 2021. SKAN Group AG was founded in 1968 and is headquartered in Allschwil, Switzerland.
Stock analysis
SKAN Group AG (SKAN) currently trades at CHF 69.70, while our model-based Fair Value estimate is CHF 23.41, 66% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of CHF 19.72 per share, and 0 of the 26 models we run sit above the CHF 69.70 price.
Bear case: the Asset-Based group reads lowest at CHF 2.97, and 26 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: CHF 15.66 (bear) to CHF 29.28 (bull), the price of CHF 69.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
SKAN Group AG reported revenue of CHF 333M in FY2025 versus CHF 234M in FY2021, a compound +9.2%/yr. Reported net income was CHF 16.3M in FY2025, compounding +11.3%/yr from FY2021.
Key figures
Market cap CHF 1.6B Small · P/E ratio 52.4 · P/S ratio 4.31 · EPS (TTM) CHF 1.33 · Dividend yield 0.3% · Net margin 8.3% · Return on equity 20.3% · Return on assets (EBIT) 8.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 73% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −66%, SKAN screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (CHF 1.12 to CHF 27.25). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
BearCHF 15.66Fair Value CHF 23.41BullCHF 29.28
Price CHF 69.70 · Downside -66.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (CHF 0.9488 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFCHF 11.66CHF 22.63CHF 42.0876
Growth DCFCHF 11.54CHF 21.58CHF 38.8975
Residual IncomeCHF 5.01CHF 6.25CHF 8.8475
All 26 models by family
DCF Models
FCF DCFCHF 11.66CHF 22.63CHF 42.0876
Owner Earningsn/aCHF 1.12CHF 3.1473
5Y Revenue ExitCHF 9.73CHF 18.05CHF 29.3670
5Y EBITDA ExitCHF 14.16CHF 27.25CHF 43.8573
5Y P/E ExitCHF 10.31CHF 19.25CHF 29.5169
10Y Revenue ExitCHF 9.91CHF 18.09CHF 30.6964
10Y EBITDA ExitCHF 13.23CHF 24.90CHF 42.9666
10Y P/E ExitCHF 10.65CHF 18.98CHF 30.8262
Earnings-Based
Graham-DoddCHF 4.92CHF 23.45CHF 32.2764
Lynch FVCHF 6.24CHF 8.92CHF 11.5961
PEG = 1.0CHF 6.24CHF 8.92CHF 11.5957
EPVCHF 7.86CHF 9.41CHF 10.7874
Dividend Discount
Gordon GGMCHF 3.70CHF 7.77CHF 12.4466
DDM Multi-StageCHF 3.70CHF 6.52CHF 8.1466
Multiples
P/E MultipleCHF 11.94CHF 15.92CHF 19.9163
P/S MultipleCHF 9.23CHF 12.30CHF 15.3858
P/B MultipleCHF 14.98CHF 19.98CHF 24.9755
EV/EBITCHF 12.76CHF 17.56CHF 22.3766
EV/EBITDACHF 16.36CHF 22.36CHF 28.3767
EV/RevenueCHF 8.63CHF 13.04CHF 17.4553
Asset-Based
NCAV (Graham)CHF 2.22CHF 2.97CHF 4.4454
Growth DCF
Growth DCFCHF 11.54CHF 21.58CHF 38.8975
Rev-Margin DCFCHF 9.73CHF 17.85CHF 28.4371
Economic Profit
Residual IncomeCHF 5.01CHF 6.25CHF 8.8475
ROIC CompounderCHF 8.99CHF 12.93CHF 18.3771
Growth Earnings
Growth-Adj P/ECHF 10.05CHF 14.36CHF 18.6767
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Start year 2020 (pandemic). Over 10 years: +32.3% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−7.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.0%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.9% vs −7.4%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 8%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +31.9% a year for the price and +13.4% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 2/14 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−66.4% · Bottom 25%
Profitability
Return on equity (12 months)20.3% · Top 25%
Return on assets3.4% · Below median
Net margin (12 months)8.3% · Below median
Operating margin (12 months)5.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)22.2% · Top 25%
Dividend yield (12 months)0.3% · Bottom 25%
Balance sheet
Debt / equity1.09× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SKAN Group AG Fair Value". https://www.fairvalue-calculator.com/stock/SKAN
Frequently asked questions
Is SKAN Group AG (SKAN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of CHF 23.41 versus a price of CHF 69.70, about 66% lower (overvalued).
What is the fair value of SKAN?
Our model-based fair value for SKAN Group AG is CHF 23.41 (as of Nov 8, 2026), built from audited fundamentals. The current price: CHF 69.70.
What is the quality score of SKAN?
SKAN Group AG has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SKAN Group AG (SKAN)?
Our model-based price target is the fair value of CHF 23.41 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario CHF 15.66, optimistic scenario CHF 29.28. It is a calculation from audited fundamentals, not an analyst target.
What is the SKAN Group AG stock forecast for 2026?
Our models put fair value at CHF 23.41, about 66% lower versus a price of CHF 69.70 (overvalued). Cautious scenario CHF 15.66, optimistic scenario CHF 29.28. The calculation is refreshed regularly with new filings.
What is the revenue of SKAN Group AG (SKAN)?
SKAN Group AG reported trailing-twelve-month revenue of about CHF 363M (latest available figure, as of Nov 8, 2026).
Does SKAN Group AG pay a dividend?
SKAN Group AG currently shows a dividend yield of 0.32% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of SKAN Group AG (SKAN) and when is the ex-dividend date?
SKAN Group AG pays a dividend of CHF 0.22 per share a year, a dividend yield of 0.3%. The last ex-dividend date was May 11, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 16.5% of earnings. Free cash flow covers the dividend 4.25 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into SKAN Group AG (SKAN)?
For today's price to be fair in a discounted-cash-flow model, SKAN Group AG would have to grow free cash flow by +32.7 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of SKAN use?
Our models discount SKAN Group AG at 8.9 %: a base by market capitalisation (mid), damped by beta 0.75, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SKAN Group AG that is +32.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has SKAN Group AG (SKAN) delivered so far?
Over the past 5 years revenue at SKAN Group AG grew +11.7 % a year. The price currently implies free-cash-flow growth of +32.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SKAN Group AG (SKAN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into SKAN Group AG (+32.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SKAN Group AG (SKAN)?
The free-cash-flow yield on the price is 1.34 %: that much free cash flow SKAN Group AG produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SKAN Group AG (SKAN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SKAN Group AG it is CHF 23.41 per share (as of Nov 8, 2026), against a price of CHF 69.70. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is SKAN Group AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, SKAN trades above its calculated fair value: price CHF 69.70, fair value CHF 23.41, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SKAN?
No. The price is what the market pays today (CHF 69.70); the fair value is what the company's own numbers justify (CHF 23.41). For SKAN Group AG the two are CHF 46.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is SKAN Group AG worth?
The market values SKAN Group AG at about CHF 1.6B (market capitalisation, as of Nov 8, 2026). Per share that is CHF 69.70; our models calculate a fair value of CHF 23.41 per share.
What do the bullish and bearish scenarios say about SKAN?
Our models span a range for SKAN Group AG: cautious scenario CHF 15.66, base CHF 23.41, optimistic CHF 29.28 per share (as of Nov 8, 2026, price CHF 69.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SKAN?
SKAN Group AG trades at a price-to-earnings ratio of 52.4 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 23.41 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings, FY2025 ex one-offs: 73.3. Other multiples: P/B 13.7, P/S 4.3, EV/EBITDA 32.1.
How solid is the balance sheet of SKAN Group AG (SKAN)?
Balance-sheet figures for SKAN Group AG (as of Nov 8, 2026): return on equity 20.3%, debt of 1.09 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is SKAN from its 52-week high?
SKAN Group AG trades at CHF 69.70, about 9% below its 52-week high of CHF 76.30 and 73% above the low of CHF 40.21 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 23.41 is for.
Which stocks are comparable to SKAN Group AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SKAN Group AG stock attractive at the current price?
The data as of Nov 8, 2026: price CHF 69.70, calculated fair value CHF 23.41 (−66%), Quality Score 53/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SKAN calculated?
We run SKAN Group AG through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of CHF 23.41 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. SKAN Group AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SKAN Group AG (SKAN)?
The closing price on Nov 6, 2026 was CHF 69.70. Our model-based fair value is CHF 23.41, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SKAN Group AG right now?
The price sits above even our optimistic bull case (CHF 29.28). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (CHF 15.66 to CHF 29.28) leaves room in how you read the outcome.
Where does the earnings growth of SKAN Group AG (SKAN) come from?
Earnings per share at SKAN Group AG grew −0.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +30.9 %, EBIT margin −21.7 %, tax rate −1.9 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of SKAN Group AG
How large is the market capitalisation of SKAN Group AG (SKAN)?
The market capitalisation of SKAN Group AG is CHF 1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SKAN Group AG (SKAN)?
The price-to-sales ratio of SKAN Group AG is 4.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SKAN Group AG (SKAN)?
Earnings per share at SKAN Group AG are CHF 1.33 (price ÷ EPS = P/E 52.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SKAN Group AG (SKAN)?
The dividend yield of SKAN Group AG is 0.3% (payout 16.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SKAN Group AG (SKAN)?
The net margin of SKAN Group AG is 8.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SKAN Group AG (SKAN)?
The return on equity (ROE) of SKAN Group AG is 20.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SKAN Group AG (SKAN)?
On an EBIT basis the return on assets of SKAN Group AG is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SKAN Group AG (SKAN)?
The operating margin of SKAN Group AG is 5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SKAN Group AG (SKAN)?
Revenue at SKAN Group AG is growing +22.2% versus a year earlier (3y avg +6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SKAN Group AG (SKAN)?
Earnings per share at SKAN Group AG are growing +0.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does SKAN Group AG (SKAN) carry?
The net debt of SKAN Group AG is CHF 37.4M (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SKAN Group AG in the live analysis
One click puts SKAN Group AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026